Latest research on Humalog

Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996.

Humalog interactions

During hospitalization, patients in CSII alone group received insulin Aspart (NovoRapid, Novo Nordisk, Bagsværd, Denmark) or insulin lispro (Humalog, Eli Lilly, USA) with an insulin pump (MiniMed 712, Medtronic, Northridge, CA) as CSII therapy, while the CSII + Lira group received liraglutide (Victoza, Novo Nordisk, Bagsvaerd, Denmark) 0.6 mg per day in addition to aforementioned CSII regimen. [source, 2016]
For glucose- and insulin-tolerance tests, 14-3-3ζKO or 14-3-3ζTAP male mice AT 10 and 25 weeks or 9 and 52 weeks, respectively, were fasted for 6 h, followed by i.p. injection of 2 g kg−1 glucose or 1.5 U kg−1 Humalog insulin (Eli Lilly, Indianapolis, IN), respectively. [source, 2015]
Medication history included Amlodipine, Aspirin, Calcium carbonate, Synthroid, Pioglitazone, Humalog, Glucovance, Crestor, Januvia, and Lisinopril. [source, 2015]
Stimulations included: insulin neutral protamine Hagedorn (NPH) (Insuman Basal, Sanofi Aventis, Paris, France), insulin glargine (Lantus, Sanofi Aventis), first metabolite of glargine (M1, Sanofi Aventis), second metabolite of glargine (M2, Sanofi Aventis), glulisine (Apidra, Sanofi Aventis), lispro (Humalog, Eli Lilly, Indianapolis, IN, USA), insulin X10 (not marketed, Novo Nordisk, Bagsvaerd, Denmark), Aspart (B28Asp, Novo Nordisk), detemir (Levemir, Novo Nordisk) and insulin-like growth factor 1 (IGF1) (Increlex, Ipsen, Basking Ridge, NJ, USA). [source, 2015]
T1D treatment involved the recombinant human insulin, NPH (67%); regular insulin (33%); synthetic rapid-acting insulin, NovoRapid (52%); and others: Humalog, Lantus, Levemir and Apidra (~10%). [source, 2015]
For those patients who are not able to adhere to or afford multiple daily insulin injections, conversion of an inpatient basal-bolus insulin regimen before discharge to a premixed insulin preparation twice a day that contains a mixture of intermediate-acting insulin neutral protamine Hagedorn and short-acting insulin formulations such as regular (Humulin R, Novolin R), Aspart (NovoLog), or lispro (Humalog) can be considered. [source, 2014]
A total of 146 insulin-naïve patients with type 2 diabetes mellitus discontinued all oral antidiabetic drugs (including met-formin, Acarbose, and sulfonylureas) and were randomized to receive either Humalog Mix 50/50 (group A) or Humalog Mix 75/25 (group B). [source, 2014]
Type 2 diabetic participants (n = 22) on insulin were instructed to replace their long-acting insulin (Lantus or Levemir) as needed with intermediate-acting insulin (NPH) and short-acting insulin (Humalog or Novolog) to ensure that their last long-acting insulin injection was at least 24 h prior to admission (36 h prior to the clamp). [source, 2014]
Studies are currently underway to compare the utility of ultrafast Aspart plus rHuPH20 and lispro plus rHuPH20 drug products with commercial Humalog as part of intensive basal-bolus insulin therapy in the treatment of type 1 and type 2 diabetes (NCT01194245 and NCT01194258, [source, 2013]
These drugs were classified into the following categories: Metformin, sulfonylureas (e.g., Glyburide, Gliclazide, Repaglinide), thiazolidinediones (TZDs, e.g., Rosiglitazone, Pioglitazone), and insulins (e.g., glargine, detemir, Humalog, lispro, NPH). [source, 2013]